Avid Bioservices Inc (CDMO)

[pphmtoolong]

Peregrine said they expected to unblind Sunrise in 2016. How does that relate to the second look-in expectation in mid 2016?

One thing that stood out for me in the CC was the detailed studies Peregrine is doing on the Bavi trial patients to zoom in on patients most likely to benefit from Bavi. This dovetails well with the current mantra of tailoring treatments to specific patients.

Why give expensive treatments to patients that are unlikely to work? I know the insurance companies will be pushing this to save money. Peregrine is wise to focus on this aspect so early in the game.

GLTA, Especially The Bavi-arm Sunrise Patients,

Paul